BioSpace

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment ...
Yahoo Finance

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation

Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed ...
Nasdaq

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad ...

CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
The American Journal of Managed Care

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

FDA late today granted accelerated approval to camizestrant for firstline treatment of patients with ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. 1 The action comes more ...
Business Wire

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the ...
Hosted on MSN

The first-ever drug aimed at pancreatic cancer’s ‘untreatable’ KRAS mutation just cleared the FDA’s safe-to-proceed letter — full phase 1/2 results drop at ASCO this ...

For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just as long, they have had no way to shut it off. The protein, KRAS, mutates in ...
Hosted on MSN

A phase 1/2 trial just reported exceptional disease control on pancreatic cancer using daraxonrasib — a targeted drug aimed at the mutation doctors once called untreatable

For roughly four decades, oncologists had a grim shorthand for the most common genetic driver of pancreatic cancer: undruggable. The KRAS protein, mutated in about 90 percent of pancreatic tumors, ...
Nasdaq

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...
Business Wire

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...